HOTH

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for dermatological disorders and unmet medical needs. Headquartered in New York, the company operates through a targeted approach to drug development, leveraging both proprietary compounds and licensed technologies. Hoth's pipeline includes BioLexa Platform for treating eczema and atopic dermatitis, which utilizes a topical zinc-based formulation, and HT-001 for the treatment of rash and skin toxicities associated with tyrosine kinase inhibitor cancer therapies. The company also develops HT-003 for acne treatment and HT-004 for psoriasis. In addition to dermatology, Hoth maintains programs in areas including wound healing and lupus. The company pursues a capital-efficient business model by partnering with research institutions and contract research organizations rather than maintaining extensive internal infrastructure. Hoth has established collaborations with institutions such as George Washington University and Virginia Commonwealth University for preclinical and clinical development activities. As a publicly traded entity on the NASDAQ under ticker symbol HOTH, the company funds operations primarily through equity financing and strategic partnerships. The company's therapeutic candidates remain in various stages of preclinical and clinical development, with ongoing efforts to advance programs through regulatory milestones and establish manufacturing partnerships for potential commercialization.